Overview

Yallaferon in Chinese Population

Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to evaluate the efficacy of Yallaferon in Chinese population with HPV-16 and/or HPV-18.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Lee's Pharmaceutical Limited
Treatments:
Interferon-alpha
Interferons
Criteria
Inclusion Criteria:

- Age 25 to 65 years of age the sex life of female patients;

- High-risk HPV 16 and/or 18 positive

- Agree to sign ICF

Exclusion Criteria:

- Cervical intraepithelial neoplasia (CIN);

- Combined with a severe fungal, trichomonas vaginitis;

- Severe primary diseases associated with cardiovascular, liver, kidney and
hematopoietic system;

- Allergies or allergy to the drug known ingredients.

- Within 30 days to accept other clinical trials of drugs or are participating in
clinical trials;

- Pregnant and lactating women and to be pregnant women;

- The researchers do not consider it appropriate clinical trials.